Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0279530 (
bone cancer
)
1,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Treatment for
bone cancer
pain remains a clinical challenge due to a poor understanding of the underlying mechanisms.
Protease-activated receptor 2
(
PAR2
), a receptor for inflammatory proteases, has been implicated in nociceptive signaling under both normal and pathologic pain states. However, little is known of the role of
PAR2
in cancer-induced bone pain. Here we investigated the potential role of
PAR2
in a rat model of
bone cancer
pain. The model of
bone cancer
pain was induced by inoculating Walker 256 into the tibia bone cavity of rats and verified by X-ray imaging, pathology, and behavior assessments. The rats with
bone cancer
exhibited marked mechanical allodynia, thermal hyperalgesia, and signs of spontaneous nocifensive behavior. Subcutaneous administration of the
PAR2
antagonist FSLLRY-NH2 almost completely abolished mechanical allodynia and thermal hyperalgesia but had no effects on spontaneous pain behavior in the rats with
bone cancer
. Immunohistochemical study revealed that the expression of
PAR2
was significantly increased in large- and medium-sized dorsal root ganglia (DRG) neurons but not in small-sized neurons after Walker 256 inoculation. These results suggest that the increased expression of
PAR2
in the DRG may contribute to the development of mechanical allodynia and thermal hyperalgesia associated with
bone cancer
rats.
PAR2
might become a novel target for the treatment of pain in patients with
bone cancer
.
...
PMID:Involvement of protease-activated receptor 2 in nociceptive behavior in a rat model of bone cancer. 2405 89
